GSK-LOC114589

Study Sponsor: GSK

Study Title

A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (bupropion XL 300mg once daily), Escitalopram oxalate (escitalopram, 10mg-20mg once daily) in Subjects with Major Depressive Disorder

Medicine or Vaccine (generic name)

bupropion

Sponsor Identification Number

LOC114589

Trial Registry Identification Number(#'s)

NCT02191397

Medical Condition

Depressive Disorder, Major

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=114589

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT02191397

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This study is available in CDISC format.

Date Added to this Site

October 2019